Schneider M, Hilgers KF (2017)
Publication Type: Journal article, other
Publication year: 2017
Book Volume: 142
Pages Range: 1282-1289
Journal Issue: 17
End stage chronic kidney disease (CKD) requiring renal replacement therapy is related to poor quality of life and high mortality. Thus, slowing the progression of CKD is an important purpose of therapy. Some general therapeutic approaches aim to slow the decline of renal function and they can be applied in all patients with CKD - irrespective of the underlying cause of CKD. A key intervention is lowering blood pressure (target: <= 140/90 mmHg, and in patients with albuminuria <= 130/80 mmHg). Inhibitors of the renin angiotensin system preferentially should be used in case of albuminuria, depending on the diabetic status and the level of albuminuria: in diabetics with albuminuria >= 30 mg/d, in non-diabetics with albuminuria > 300 mg/d. Mineralocorticoid receptor blockers and endothelin receptors blockers promise novel anti-proteinuric strategies - but still validation of their positive effects on retarding CKD progression is necessary. In patients with diabetic kidney disease, glycemic control aiming for an HbA1c of ? 7.0 % has been established to slow CKD progression. Furthermore, SGLT-2 inhibition with empagliflozin may be considered as a new therapeutic approach that provides additional cardiovascular and renal protection. Finally, recent studies suggest: correction of metabolic acidosis and avoidance of episodes of acute renal failure may provide protection against the progression of CKD.
APA:
Schneider, M., & Hilgers, K.F. (2017). How to Retard Progression of Chronic Kidney Disease. Deutsche Medizinische Wochenschrift, 142(17), 1282-1289. https://dx.doi.org/10.1055/s-0042-115782
MLA:
Schneider, Markus, and Karl Friedrich Hilgers. "How to Retard Progression of Chronic Kidney Disease." Deutsche Medizinische Wochenschrift 142.17 (2017): 1282-1289.
BibTeX: Download